Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Brief Description  
The purpose of this study is to learn more about the safety, effect and tolerability of 2 different treatment regimens of telaprevir (telaprevir taken every 8 hours per day or telaprevir taken 2 times per day) together with standard treatment pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C infection who have not received previous treatment. Telaprevir is an investigational drug for Hepatitis C which targets the Hepatitis C virus and damages its ability to crea
Who may be Eligible  
Adult men and women between 18 and 70 years of age with genotype 1 chronic Hepatitis C infection that have not been previously treated. Subjects may have compensated cirrhosis.
Hepatitis C
IRB Number  
Principal Investigator  
Bonkovsky, Herbert

For More Information, Contact  Gale  W, Groseclose
Phone:  (704) 355-4875  Fax:  (704) 355-9641  
Email:  gale.groseclose@carolinashealthcare.org
Address:1000 Blythe Boulevard MEB, Ste. 103 Charlotte, NC 28203